Coming soon.  

We are pleased to let you know that CEEGOG has been approved as a provisional member of GCIG – the Organization of International Cooperative Groups for Clinical Trials in Gynecologic Cancers. 

The Gynecological Cancer InterGroup aims to promote and facilitate high quality  clinical trials in order to improve the outcomes for women with gynecological cancer. CEEGOG could be interested in joining some of the GCIG protocols, and GCIG can be a good network for boosting your projects in the future. 

After two years of provisional membership, a re-evaluation for full membership is conducted (which also applies to all full membership groups every two years). One criterion is that CEEGOG works as a group, which means that several CEEGOG centers participate in GCIG trials. We look forward to cooperating with your centers within the GCIG trials and projects! 

Coming soon.  

Coming soon.  

David Cibula participated in the GCIG CCRN (Cervix Cancer Research Network) Education symposium where he introduced our collaborative group and activities. He talked about all CEEGOG academic trials, and about the CEEGOG responsibilities related to conducting the ENGOT trials in our region. He also mentioned the role of the CEEGOG office, and highligted the importance of Study coordinating training at the CEEGOG office in Prague. 

CEEGOG has been expanding, and  a well functioning network among 39 centers within 8 countries in Central and Eastern Europe has been established. It is our pleasure to invite for collaboration the newly approved sites to be involved in CEEGOG from Croatia, Macedonia, Serbia, Romania. 

Coming soon.  

We would like to invite CEEGOG members, colleagues, study coordinators and friends to the CEEGOG conference to be held in Prague on December 8 – 9, 2017. The deadline for receiving  abstracta is October 15, 2017.

Conference program:
Scientific sessions:                 Ongoing clinical trials, unanswered Q and research opportunities
Endometrial cancer
Surgical treatment of cervical cancer
Surgical treatment of ovarian cancer
Systematic treatment of ovarian cancer
BRCA 1 and 2 mutation carriers
 
Workshops:                             Designing a clinical trial
Assessment of quality, safety and morbidity in surgical trials
Trial design, size of the group, interim analysis
Primary end points and surrogate end points
Writing the protocol
 
CEEGOG meeting:                   Overview of ongoing commercial and non-commercial trials
Free communication session
How to facilitate further collaboration
Proposals for new trials
CEEGOG related issues
 
Invited speakers:
Philipp Harter    Kliniken Essen-Mitte, University Duisburg-Essen, Germany
Mansoor Raza Mirza     Copenhagen University Hospital, Denmark 
Ladislav Dusek Institute for Biostatistics and Analyses, Masaryk University, Brno, Czech Republic
 
You are welcome to contact the CEEGOG office for further information The invitation card and the agenda will be sent on request. We look forward to meeting you in Prague!
The conference is supported by educational grants provided by the Roche company, AstraZeneca and GlaxoSmithKline, s. r. o.

Coming soon.  

Coming soon.  

 Coming soon. 

  1. c
  2. Change of the CEEGOG residence, June 2017
  3. Minutes of the ENGOT Phase I/II group meeting, April 29, 2017, Zürich
  4. The third series of Gynaecological Cancer Academy workshops, March 2017
  5. ENGOT meeting in Valencia, March 3 – 4, 2017
  6. SOLO3 trial, February 2017
  7. Eight countries in CEEGOG, December 2016
  8. CEEGOG meeting in Prague on December 9, 2016
  9. ENGOT meeting in Malmö, October 6 – 7, 2016
  10. Gynaecological Cancer Academy (GCA) on September 30, 2016